Furthermore, we evaluated the association between plasma FEZF1-AS1 expression and clinicopathological features of NSCLC, and discovered that high plasma FEZF1-AS1 levels were strongly associated with male gender (P = .018), positive smoking status (P ≤ .001), advanced clinical stage (P ≤ .001), positive distant metastasis (P ≤ .001), positive lymph node metastasis (P ≤ .001), and larger tumor size (P ≤ .001). The gene discussed is FEZF1; the disease is non-small cell lung carcinoma.